# BridgeBio Pharma, Inc. (BBIO) FY2026 YTD Q3 Statement of Cash Flows

- Company: BridgeBio Pharma, Inc. (BBIO)
- Period: 2026-01-01 to 2026-09-30
- Filing: Q3 FY2026 10-Q, filed 2026-10-29, accession number 0001743881-26-000034
- Page: https://plicit.ai/financials/bbio/fy2026-ytd-q3-cash-flow
- Chart image: https://plicit.ai/charts/bbio-fy2026-ytd-q3-cash-flow-sankey.png

## Chart details

Cash flows for Jan 1, 2026 through Sep 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations. Beginning cash: Dec 31, 2025. Ending cash: Sep 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

- **Beginning cash on Dec 31, 2025**: 572,140,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations
- **Operating activities**: negative 312,550,000 US dollars. Net cash used.
- **Net loss**: negative 382,942,000 US dollars
- **Stock-based compensation**: 117,171,000 US dollars
- **Loss on extinguishment of debt**: 0 US dollars
- **Noncash interest expense on deferred royalty obligations**: 123,500,000 US dollars
- **Amortization of debt discount and issuance costs**: 5,670,000 US dollars
- **Depreciation and amortization**: 3,308,000 US dollars
- **Noncash lease expense**: 4,714,000 US dollars
- **Net loss from equity method investments**: 32,030,000 US dollars
- **Change in fair value of the embedded derivative associated with the deferred royalty obligation**: negative 7,098,000 US dollars
- **Other noncash adjustments, net**: 2,233,000 US dollars
- **Accounts receivable, net**: negative 235,646,000 US dollars
- **Inventories**: negative 35,641,000 US dollars
- **Prepaid expenses and other current assets**: negative 26,872,000 US dollars
- **Other assets**: negative 5,849,000 US dollars
- **Accounts payable**: 51,993,000 US dollars
- **Accrued compensation and benefits**: negative 9,049,000 US dollars
- **Accrued research and development liabilities**: 13,583,000 US dollars
- **Operating lease liabilities**: negative 5,494,000 US dollars
- **Deferred revenue**: negative 6,558,000 US dollars
- **Other liabilities**: 48,397,000 US dollars
- **Noncash income from an equity method investment**: 0 US dollars
- **Investing activities**: 11,761,000 US dollars. Net cash provided.
- **Purchases of marketable securities**: negative 63,937,000 US dollars
- **Maturities of marketable securities**: 76,500,000 US dollars
- **Payment for intangible assets**: 0 US dollars
- **Purchases of property and equipment**: negative 802,000 US dollars
- **Proceeds from special cash dividends received from an investment in equity securities**: 0 US dollars
- **Financing activities**: 1,264,137,000 US dollars. Net cash provided.
- **Proceeds from issuance of 2033 Notes /2031 Notes - 2031 Notes, net**: 0 US dollars
- **Proceeds from issuance of 2033 Notes /2031 Notes - 2033 Notes, net**: 632,500,000 US dollars
- **Issuance costs and discounts associated with 2033 Notes/2031 Notes - 2031 Notes, net**: 0 US dollars
- **Issuance costs and discounts associated with 2033 Notes/2031 Notes - 2033 Notes, net**: negative 13,227,000 US dollars
- **Repayment of term loans**: 0 US dollars
- **Proceeds from royalty obligation under Royalty Purchase Agreement (as described in Note 9)**: 0 US dollars
- **Issuance costs associated with royalty obligation under Royalty Purchase Agreement**: 0 US dollars
- **Repayments of deferred royalty obligations**: negative 62,507,000 US dollars
- **Proceeds from issuance of preferred stock**: 933,900,000 US dollars
- **Issuance costs associated with preferred stock**: negative 1,342,000 US dollars
- **Payment of preferred stock dividends**: negative 2,694,000 US dollars
- **Repurchase of common stock**: negative 252,502,000 US dollars
- **Proceeds from stock option exercises, net of repurchases**: 33,712,000 US dollars
- **Proceeds from common stock issuances under ESPP**: 9,728,000 US dollars
- **Repurchase of RSU shares to satisfy tax withholding**: negative 13,431,000 US dollars
- **Transactions with noncontrolling interests**: 0 US dollars
- **Operating adjustment reconciliation**: 715,149,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
- **financing gross reconciliation**: 1,609,840,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
- **investing gross reconciliation**: 76,500,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
- **Exchange-rate effect**: 0 US dollars
- **Ending cash on Sep 30, 2026**: 1,535,488,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations
- **Cash sources and uses**: 1,848,038,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
- **Net cash change**: 963,348,000 US dollars. Ending cash minus beginning cash.
- **Cash flow / Net income**: Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.
- **Operating cash flow**: negative 312,550,000 US dollars. Operating cash flow used in the free cash flow calculation.
- **Cash purchases of property, plant and equipment**: 802,000 US dollars. These cash purchases are already included in investing activities above.
- **Free cash flow**: negative 313,352,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

### Chart connections

- Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
- Financing contributions meet at a reconciliation junction before connecting to the net cash total.
- Investing contributions meet at a reconciliation junction before connecting to the net cash total.
- Operating reconciliation adjustments are not all independent cash receipts.
- Net loss −$382.94M + net operating adjustments $70.39M = operating cash −$312.55M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
- Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
- The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
- Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: negative 312,550,000 US dollars minus 802,000 US dollars equals negative 313,352,000 US dollars.
